Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Adams, Richard A.Fisher, David J.Graham, JanetSeligmann, Jenny F.Seymour, MatthewKaplan, RichardYates, EmmaParmar, MaheshRichman, Susan D.Quirke, PhilipButler, RachelBrown, EwanCollinson, FionaFalk, StephenWasan, HarpreetShiu, Kai-KeenMiddleton, GarySamuel, LeslieWilson, Richard H.Brown, Louise C.Maughan, Timothy S.FOCUS Trial Collaboration2021-11-242021-11-242021-11-20Adams, R A, Fisher, D J, Graham, J, Seligmann, J F, Seymour, M, Kaplan, R, Yates, E, Parmar, M, Richman, S D, Quirke, P, Butler, R, Brown, E, Collinson, F, Falk, S, Wasan, H, Shiu, K-K, Middleton, G, Samuel, L, Wilson, R H, Brown, L C, Maughan, T S & FOCUS Trial Collaboration 2021, 'Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial', Journal of Clinical Oncology, vol. 39, no. 33, JCO.21.01436, pp. 3693-3704. https://doi.org/10.1200/JCO.21.014360732-183XRIS: urn:DD8C999877AC6619E48FC8DE1CC26E8BORCID: /0000-0002-8402-8670/work/100345920https://hdl.handle.net/2164/17553SUPPORT Supported by Cancer Research UK and the National Institute for Health Research (NIHR).421052347engSDG 3 - Good Health and Well-beingR MedicineCancer Research UKNational Institute for Health Research (NIHR)RCapecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N TrialJournal article10.1200/JCO.21.014363933